SecBot SecBot
SECBOTREPLAY Home › Report › AZR

AZR · Board reconstituted +9.9M shares

Azora Therapeutics, Inc. (DE) · 8-K filed Nov 9, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Nov 9, 2026 at 07:30 ET

Azora Therapeutics appointed three new independent directors (Aida Habtezion, Paul Hastings, Thomas Soloway) and four prior directors resigned, reducing the board to five members. Separately, 9,924,260 shares of common stock were issued upon automatic conversion of Series A Preferred Stock, increasing the share count to 14,243,129. The board changes follow a contested annual meeting and the conversion resolves the shareholder approval condition for Nasdaq listing rules.

  • Three new independent directors appointed on November 3, 2026: Aida Habtezion (Pfizer CMO), Paul Hastings (Nkarta CEO), Thomas Soloway (T-knife CEO).
  • Four directors resigned: J. Kermit Anderson, Cary J. Claiborne, Robertson H. Gilliland, Kevin Schuyler; resignations not due to disagreements.
  • Board reduced to five members; Matthew Davidson appointed chair.
  • 9,924.260 shares of Series A Preferred Stock automatically converted into 9,924,260 shares of common stock on November 2, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access